CVS Health Unveils Structural Overhaul

CVS Health recently initiated a partial corporate split that, at first glance, projects a bold operational shift. Yet, industry analysts point out that the enterprise's most influential and lucrative segments remain securely consolidated under one roof. This strategic maneuver could inadvertently ignite renewed legislative efforts in Congress aimed at forcibly breaking apart the conglomerate and its industry peers.

Currently, CVS Health houses an array of diverse business sectors, spanning health insurance, pharmacy benefit management (PBM), pharmacy services, and direct healthcare provision. This extensive vertical integration stems from a series of high-profile mergers and acquisitions designed to maximize corporate efficiency. However, the corporation has now announced plans to detach its retail pharmacy operations by 2028. This planned independent, publicly traded entity—to be called CVS Pharmacy—will encompass approximately 9,000 retail drugstores, in-store MinuteClinics, mail-order channels, and digital health platforms. Meanwhile, the parent entity, CVS Health, will retain insurance giant Aetna, PBM leader CVS Caremark, clinical care networks Oak Street Health and Signify Health, and the CVS Specialty drug division.

The Legislative Push Against Healthcare Monopolies

Bipartisan momentum is building to dismantle vertically integrated giants that currently govern over 80% of prescription drugs nationwide. Alongside CVS Health, corporations such as UnitedHealthcare and Cigna dominate this space. Since the late 2010s, PBMs and specialty pharmacies have evolved into central, highly profitable pillars of these massive healthcare empires.

Operating as vital middlemen within the pharmaceutical pipeline, PBMs adjudicate prescription claims, manage pharmaceutical benefits for insurers, employers, and government agencies, construct and oversee drug formularies, establish pharmacy networks, and negotiate drug pricing alongside manufacturer rebates. Simultaneously, specialty pharmacies distribute high-cost, intricate medications tailored for individuals battling severe, chronic, or rare medical conditions.

The deep integration of PBMs and specialty pharmacies within major healthcare networks has drawn intense scrutiny from lawmakers across the political spectrum, who frequently cite anticompetitive behavior. Critics argue that these sprawling conglomerates leverage their immense scale to channel patients exclusively toward their proprietary pharmacies, driving up drug prices for consumers, businesses, and public programs while squeezing independent pharmacies out of the market.

The only way to make healthcare more affordable is to break up these healthcare conglomerates. — Senator Elizabeth Warren

Introduced by Senators Elizabeth Warren (D-MA) and Josh Hawley (R-MO), the Break Up Big Medicine Act stands out as a key legislative proposal designed to compel companies like CVS to permanently separate their insurance, PBM, and healthcare provider arms into distinct, independent entities.

In an official statement, Senator Warren emphasized the heavy financial burden created by corporate complexity, pointing out that independent doctors and pharmacists are continually priced out of a fair market. Conversely, the Pharmaceutical Care Management Association—a national trade group advocating for PBMs such as CVS Caremark—has strongly opposed the bill, framing it as a threat to affordable healthcare and attributing rising drug costs directly to the pharmaceutical manufacturing sector instead.

Will the Corporate Split Satisfy Lawmakers?

Despite the industry pushback, CVS Health CEO David Joyner acknowledged on CNBC that the Break Up Big Medicine legislation served as a primary catalyst for the company's decision to divide its operations.

Even so, the announced spin-off is unlikely to appease critical lawmakers. Under the proposed restructuring, CVS Health will maintain ownership of Aetna, Caremark, Oak Street Health, and CVS Specialty beneath a unified corporate banner. Former health insurance executive and whistleblower Wendell Potter noted that this leaves the core components driving regulatory concern entirely untouched.

Ultimately, the actions taken by CVS Health address only a fraction of the sweeping reforms outlined by Senators Warren and Hawley. Their legislation seeks to outright ban PBM parent companies from operating retail or specialty pharmacies—particularly lucrative units that heavily dictate patient medication choices and out-of-pocket expenses. Furthermore, the proposed statute would bar health insurers, PBMs, and drug wholesalers from sharing common ownership with medical service providers or pharmacies.

As voter concerns regarding out-of-pocket healthcare costs dominated recent elections, shifting political dynamics could accelerate bipartisan pushes to compel healthcare conglomerates to divest their PBM and specialty pharmacy divisions in the name of consumer affordability.